Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose Escalation Study of GC4419 in Combination With Radiation and Chemotherapy for Squamous Cell Cancers of the Head and Neck.

Trial Profile

A Phase 1 Dose Escalation Study of GC4419 in Combination With Radiation and Chemotherapy for Squamous Cell Cancers of the Head and Neck.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avasopasem manganese (Primary) ; Cisplatin (Primary)
  • Indications Head and neck cancer; Mucositis; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Galera Therapeutics

Most Recent Events

  • 18 May 2020 According to a Galera Therapeutics media release, the company will discuss summary of the preliminary findings from the study will be discussed in a virtual Key Opinion Leader (KOL) event on cisplatin-induced chronic kidney disease on Friday, May 22, 2020, from 10 a.m. to 11 a.m. EDT. An archived version of the webcast will be available in the News & Events section of the Investors page of Galera's website for 60 days following the event.
  • 30 Apr 2020 According to a Galera Therapeutics media release, data from this trial were accepted for presentation at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program, taking place May 29-31, 2020.
  • 27 Sep 2016 Results (n=46) published in the Galera Therapeutics Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top